Please try another search
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Name | Age | Since | Title |
---|---|---|---|
Ilan Katz | 48 | - | Director |
Jeffrey G. Spragens | 79 | 2020 | Independent Non-Executive Chairman of the Board |
Samuel J. Reich | 46 | 2020 | CEO, CFO & Director |
James J. Martin | 54 | 2020 | Independent Director |
Stephen D. Collins | 68 | 2020 | Independent Director |
William Polvino | - | 2021 | Director |
David Link | - | 2021 | Director |
Eddie Joe Sullivan | - | 2021 | Director |
Christine Hamilton | - | 2021 | Director |
Mervyn Turner | - | 2021 | Director |
William J. Polvino | 61 | 2019 | Independent Director |
Jim Robl | - | - | Member of Scientific Advisory Board |
Christine E. Hamilton | 65 | - | Co-Founder & Independent Director |
Arturo Casadevall | - | - | Member of Scientific Advisory Board |
Michael Haller | - | - | Member of Scientific Advisory Board |
Stephen E. Gitelman | - | 2020 | Member of Scientific Advisory Board |
Helen K. Ellias | - | 2023 | Director |
Samuel J. Reich | 49 | 2020 | CEO & Executive Chairman |
David Charles Link | 69 | 2018 | Independent Vice Chairman |
Eddie Joe Sullivan | 57 | 2014 | Co-Founder, President & Director |
Scott Giberson | 54 | 2022 | Independent Director |
Jeffrey G. Spragens | 82 | 2020 | Independent Director |
Mark J. Ratain | 69 | 2022 | Member of Scientific Advisory Board |
Erick J. Lucera | 56 | 2023 | Independent Director |
Juan Alvarez | - | 2022 | Member of Scientific Advisory Board |
Helen Katherine Ellias | 45 | 2023 | Independent Director |
Andrew D. Moin | 40 | 2023 | Independent Director |
Edward D. Hamilton | - | 2021 | Co-Founder & Board Observer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review